Sipuleucel-T -- Benefit Assessment According to §35a Social Code Book V [Internet].

The aim of the present report was to assess the added benefit of sipuleucel-T versus the appropriate comparator therapy (ACT) for treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate-resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated.

http://ift.tt/2seWJRi